Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2011

View Archived Issues

Small-molecule inhibitors of ezrin developed to target bone cancer

U.S. study uncovers candidate SNPs associated with susceptibility to cold sores

Vertex Pharmaceuticals synthesizes novel products

Isis Pharmaceuticals expands pipeline

DSMB recommends continuation of VISTA-16 trial

Vernalis and Lundbeck collaboration reaches second milestone

Neovacs completes recruitment in phase II TNF-Kinoid trial

New inhibitor of cyclin-dependent kinase 9 shows preclinical potential in CLL

Chugai Pharmaceutical presents new MEK 1 inhibitor

Novel biomarker for B-cell lymphoma discovered in Japan

New prodrugs of a coagulation factor VIIa inhibitor designed by Eisai

Novel GPR52 receptor agonists disclosed by Takeda Pharmaceutical

U.K. team presents novel cyclophilin inhibitors

New chelating cyclopeptides prepared by French group

Impax advances IPX-159 to phase IIb testing

FDA clears assay to help predict prognosis of patients with heart failure

Millennium Pharmaceuticals patents new histone deacetylase 6 inhibitors

Sanofi sells Dermik

Rib-X Pharmaceuticals reports data from phase IIb delafloxacin study

NeurogesX gives update on Qutenza sNDA

Gilead Sciences submits sNDA for Truvada

StemCells completes treatment of first cohort in phase I/II spinal cord injury trial

Dicerna and Kyowa Hakko Kirin select DsiRNA candidate for development

ThromboGenics and BioInvent complete enrollment in phase IIb TB-402 study

FDA does not require REMS program for Korlym in Cushing's syndrome

Vertex gives update on Kalydeco NDA and MAA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...